Company:  MALLINCKRODT PLC (MNK)
Form Type:  8-K
Filing Date:  2/13/2018 
CIK:  0001567892 
Address:  3 LOTUS PARK, THE CAUSEWAY
STAINES-UPON-THAMES
 
City, State, Zip:  SURREY,  TW18 3AG 
Telephone:  44-017-8463-6700 
Fiscal Year:  12/29 
Last Trade
Last Trade: 
$13.89  
Change: 
-0.10 (-0.72%)  
Trade Time: 
01:08 PM EST  
Market Cap: 
$1.20B
Trade MNK now with 

© 2018  
Description of Business
We are a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. In the past few years, we have executed on Mallinckrodt's ongoing transformation to become an innovation-driven specialty pharmaceuticals growth company through a series of strategic acquisitions and divestitures, developing strong commercial platforms and an increasingly robust pipeline. In doing so, our emphasis has evolved to focus on a development portfolio of treatments for severe and critically ill infants and adults.
Register and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement.
    SECTION 2 FINANCIAL INFORMATION
      Item 2.01. Completion of Acquisition or Disposition of Assets.
      Item 2.03. Creation of a Direct Financial Obligation or an ...
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    Exhibit Index
    SIGNATURES